Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Oncolytics Biotech Inc. (T:ONC)

Business Focus: Biotechnology & Medical Research

This company is also listed in the United States as ONCY on the NASDAQ. Click here to get the live US quote and see if there are any SEC insider filings..
Nov 19, 2020 08:05 am ET
Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 19, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety a
Nov 19, 2020 08:05 am ET
Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 19, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the s...
Nov 17, 2020 08:05 am ET
Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium
SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 17, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of three abstracts for electronic poster presentations to be given as part of the 2020 San Antonio Breast Cancer Symposium, which is being held virtually from December 8-11, 2020.
Nov 17, 2020 08:05 am ET
Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium
SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 17, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of three abstracts for electronic poster presentations to be given as part of the 2020 San Antonio Breast Cancer Symposium, which is being held virtually from December 8-11, 2020. ...
Nov 11, 2020 03:01 pm ET
Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
SAN DIEGO, and CALGARY, AB, Nov. 11, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted....
Nov 11, 2020 03:01 pm ET
Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
SAN DIEGO, and CALGARY, AB, Nov. 11, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Nov 09, 2020 07:05 am ET
Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting
- AWARE-1 data support the results of a prior phase 2 trial that showed a near doubling of overall survival with pelareorep treatment in HR+/HER2- breast cancer patients
Nov 09, 2020 07:05 am ET
Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting
- AWARE-1 data support the results of a prior phase 2 trial that showed a near doubling of overall survival with pelareorep treatment in HR+/HER2- breast cancer patients...
Nov 09, 2020 06:05 am ET
Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. [NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting. The abstract highlights clinical data from ReoGlio, an investigator-sponsored phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of patients with newly diagnosed glioblastoma mult...
Nov 09, 2020 06:05 am ET
Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2020 /CNW/ -- Oncolytics Biotech® Inc. [NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting. The abstract highlights clinical data from ReoGlio, an investigator-sponsored phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of patients with newly diagnosed glioblastoma multiforme
Nov 06, 2020 06:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
- Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET...
Nov 06, 2020 06:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
- Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET
Oct 27, 2020 07:00 am ET
Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor
Multi-center trial to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple GI cancer indications
Oct 27, 2020 07:00 am ET
Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor
Multi-center trial to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple GI cancer indications...
Oct 07, 2020 07:00 am ET
Oncolytics Biotech® to Participate in BIO Investor Forum Digital
SAN DIEGO and CALGARY, AB, Oct. 7, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be participating in the BIO Investor Forum Digital, which is taking place virtually from October 13-15, 2020.
Sep 01, 2020 09:25 am ET
Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences
SAN DIEGO and CALGARY, Alberta, Sept. 1, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September:
Aug 26, 2020 07:00 am ET
Aug 10, 2020 07:00 am ET
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference
SAN DIEGO, Calif. and CALGARY, AB, Aug. 10, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the Canaccord Genuity 40th Annual Growth Conference. Presentation details are listed below.
Aug 04, 2020 04:01 pm ET
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta, Aug. 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted....
Aug 04, 2020 04:01 pm ET
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta, Aug. 4, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Jul 29, 2020 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, AB, July 29, 2020 /PRNewswire/ --- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Tuesday, August 4, 2020, at 4:30 pm ET to discuss a corporate update and financial results for the second quarter of 2020....
Jul 29, 2020 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, AB, July 29, 2020 /CNW/ --- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Tuesday, August 4, 2020, at 4:30 pm ET to discuss a corporate update and financial results for the second quarter of 2020.
Jun 25, 2020 07:00 am ET
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
SAN DIEGO and CALGARY, Alberta, June 25, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TNBC) study to be managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in patients with unresectable locally advanced or metastatic TNBC.
Jun 25, 2020 07:00 am ET
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
SAN DIEGO and CALGARY, Alberta, June 25, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TNBC) study to be managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in patients with unresectable locally advanced or metastatic TNBC. ...
Jun 23, 2020 07:00 am ET
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
SAN DIEGO and CALGARY, Alberta, June 23, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC). The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business in the US and Canada as EMD Serono, and Pfizer Inc. (NYSE: PFE). Participants in the study receive paclitaxel, pelareorep in combination with paclitaxel alon
Jun 23, 2020 07:00 am ET
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
SAN DIEGO and CALGARY, Alberta, June 23, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in HR+/HER2- metastatic breast cancer (mBC). The study, known as BRACELET-1, is being conducted under a co-development agreement with Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business in the US and Canada as EMD Serono, and Pfizer Inc. (NYSE: PFE). Participants in the study receive paclitaxel, pelareorep in combination with paclitax...
Jun 15, 2020 08:15 pm ET
Oncolytics Biotech® Establishes New At-The-Market Facility
SAN DIEGO, Calif. and CALGARY, Alberta, June 15, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to $40 million over the course of the next 25 months. The company has no obligation to sell any shares pur...
Jun 15, 2020 08:15 pm ET
Oncolytics Biotech® Establishes New At-The-Market Facility
SAN DIEGO, Calif. and CALGARY, Alberta, June 15, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to $40 million over the course of the next 25 months. The company has no obligation to sell any shares pursuant t
Jun 04, 2020 07:00 am ET
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
SAN DIEGO, California and CALGARY, Alberta, June 4, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canaccord Genuity and held on June 2, 2020. The call focused on recently announced clinical data from Oncolytics' AWARE-1 study presented at the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Meeting 2020 and highlighted the ability of pelareorep to induce a pro-inflammatory tumor microenvironment across multiple breast cancer subtypes.
Jun 04, 2020 07:00 am ET
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
SAN DIEGO, California and CALGARY, Alberta, June 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canaccord Genuity and held on June 2, 2020. The call focused on recently announced clinical data from Oncolytics' AWARE-1 study presented at the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Meeting 2020 and highlighted the ability of pelareorep to induce a pro-inflammatory tumor microenvironment across multiple breast cancer subtypes. ...
May 29, 2020 07:00 am ET
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
SAN DIEGO and CALGARY, Alberta, May 29, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical proof-of-concept data from the Company's phase 1b study in carfilzomib-refractory multiple myeloma patients treated with pelareorep in combination with carfilzomib (Kyprolis®). Data presented in the ePoster demonstrates that the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep in canc
May 29, 2020 07:00 am ET
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
SAN DIEGO and CALGARY, Alberta, May 29, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical proof-of-concept data from the Company's phase 1b study in carfilzomib-refractory multiple myeloma patients treated with pelareorep in combination with carfilzomib (Kyprolis®). Data presented in the ePoster demonstrates that the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep ...
May 26, 2020 07:00 am ET
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
SAN DIEGO and CALGARY, Alberta, May 26, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study. The data demonstrates a pelareorep-induced adaptive immune response in the tumor microenvironment (TME) and the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep. The ePos
May 26, 2020 07:00 am ET
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
SAN DIEGO and CALGARY, Alberta, May 26, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster (ePoster) with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study. The data demonstrates a pelareorep-induced adaptive immune response in the tumor microenvironment (TME) and the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep. T...
May 14, 2020 07:00 am ET
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
SAN DIEGO and CALGARY, Alberta, May 14, 2020 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of two abstracts in connection with the upcoming ASCO Virtual Annual Meeting on May 29-31. The first abstract ("Multiple Myeloma Abstract"), which has been accepted as an electronic poster, reports on viral replication, tumor immune responses, and treatment safety in multiple myeloma patients treated with pelareorep in combination with carfilzomib (Kyprolis®). The second a
May 14, 2020 07:00 am ET
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
SAN DIEGO and CALGARY, Alberta, May 14, 2020 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of two abstracts in connection with the upcoming ASCO Virtual Annual Meeting on May 29-31. The first abstract ("Multiple Myeloma Abstract"), which has been accepted as an electronic poster, reports on viral replication, tumor immune responses, and treatment safety in multiple myeloma patients treated with pelareorep in combination with carfilzomib (Kyprolis®). The s...
May 13, 2020 07:00 am ET
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
SAN DIEGO and CALGARY, Alberta, May 13, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will present during the RBC Global Healthcare Conference at 1:55 pm Eastern Time on Wednesday, May 20, 2020. The conference is being held on May 19 & 20 in a virtual format.
May 13, 2020 07:00 am ET
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
SAN DIEGO and CALGARY, Alberta, May 13, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will present during the RBC Global Healthcare Conference at 1:55 pm Eastern Time on Wednesday, May 20, 2020. The conference is being held on May 19 & 20 in a virtual format....
May 08, 2020 07:00 am ET
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO and CALGARY, Alberta, May 8, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of Shareholders held on Thursday May 7, 2020.  A total of 54.32% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting....
May 08, 2020 07:00 am ET
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO and CALGARY, Alberta, May 8, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of Shareholders held on Thursday May 7, 2020.  A total of 54.32% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
May 08, 2020 07:00 am ET
Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta, May 8, 2020 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted....
May 08, 2020 07:00 am ET
Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta, May 8, 2020 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.
May 04, 2020 07:00 am ET
Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting
SAN DIEGO and CALGARY, Alberta, May 4, 2020 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract for an electronic-poster (ePoster) to be presented as part of the ESMO Breast Cancer Virtual Meeting on May 23 & 24, 2020. The abstract highlights preliminary data on viral replication and a pelareorep-induced adaptive immune response in tumors from the Company's window-of-opportunity study, AWARE-1. The study combines the appropriate intervention for the
May 04, 2020 07:00 am ET
Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting
SAN DIEGO and CALGARY, Alberta, May 4, 2020 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract for an electronic-poster (ePoster) to be presented as part of the ESMO Breast Cancer Virtual Meeting on May 23 & 24, 2020. The abstract highlights preliminary data on viral replication and a pelareorep-induced adaptive immune response in tumors from the Company's window-of-opportunity study, AWARE-1. The study combines the appropriate intervention ...
Apr 30, 2020 07:00 am ET
Oncolytics Biotech® Announces Changes to Annual General Meeting
SAN DIEGO and CALGARY, Alberta, April 30, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") today announced that in light of the ongoing COVID-19 pandemic, it is taking precautionary measures for its upcoming 2020 Annual General Meeting (the "Meeting") to be held at 4:30 p.m. (Toronto time) on May 7, 2020....
Apr 30, 2020 07:00 am ET
Oncolytics Biotech® Announces Changes to Annual General Meeting
SAN DIEGO and CALGARY, Alberta, April 30, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), (the "Company") today announced that in light of the ongoing COVID-19 pandemic, it is taking precautionary measures for its upcoming 2020 Annual General Meeting (the "Meeting") to be held at 4:30 p.m. (Toronto time) on May 7, 2020.
Apr 17, 2020 05:13 pm ET
Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
SAN DIEGO, California and CALGARY, Alberta, April 17, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided an update on the potential impact of COVID-19 on the Company's clinical and business operations. The Company's clinical and regulatory teams remain active and are working closely with our investigators to identify the most appropriate steps forward for each study. There has been no impact on the continuity of the manufacturing of pelareorep, and Oncolytics is fully capable of
Apr 17, 2020 05:13 pm ET
Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
SAN DIEGO, California and CALGARY, Alberta, April 17, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided an update on the potential impact of COVID-19 on the Company's clinical and business operations. The Company's clinical and regulatory teams remain active and are working closely with our investigators to identify the most appropriate steps forward for each study. There has been no impact on the continuity of the manufacturing of pelareorep, and Oncolytics is fully capa...
Apr 02, 2020 07:00 am ET
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
SAN DIEGO and CALGARY, Alberta, April 2, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced positive clinical data published in a peer-reviewed journal highlighting that the combination of FOLFIRI, bevacizumab and pelareorep was well tolerated, with promising efficacy signals in colorectal cancer patients with KRAS mutated tumors. The article, entitled "Elucidation of Pelareorep Pharmacodynamics in a Phase I Trial in Patients with KRAS Mutated Colorectal Cancer," authored by Dr.
Apr 02, 2020 07:00 am ET
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
SAN DIEGO and CALGARY, Alberta, April 2, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced positive clinical data published in a peer-reviewed journal highlighting that the combination of FOLFIRI, bevacizumab and pelareorep was well tolerated, with promising efficacy signals in colorectal cancer patients with KRAS mutated tumors. The article, entitled "Elucidation of Pelareorep Pharmacodynamics in a Phase I Trial in Patients with KRAS Mutated Colorectal Cancer," authored...
Mar 24, 2020 05:06 pm ET
IIROC Trade Resumption - ONC
TORONTO, March 24, 2020 /CNW/ - Trading resumes in:
Mar 24, 2020 02:47 pm ET
IIROC Trading Halt - ONC
TORONTO, March 24, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 24, 2020 12:54 pm ET
IIROC Trade Resumption - ONC
TORONTO, March 24, 2020 /CNW/ - Trading resumes in:
Mar 24, 2020 12:39 pm ET
IIROC Trading Halt - ONC
TORONTO, March 24, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 24, 2020 10:31 am ET
IIROC Trade Resumption - ONC
TORONTO, March 24, 2020 /CNW/ - Trading resumes in:
Mar 24, 2020 10:26 am ET
IIROC Trading Halt - ONC
TORONTO, March 24, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 24, 2020 07:00 am ET
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
SAN DIEGO, California and CALGARY, Alberta, March 24, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1.  Consistent with the safety run-in with patients receiving pelareorep and Tecentriq®, Cohort 1 demonstrated widespread viral replication in the majority of tumors with the creation of a pro-inflammatory effect in the t
Mar 24, 2020 07:00 am ET
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
SAN DIEGO, California and CALGARY, Alberta, March 24, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1.  Consistent with the safety run-in with patients receiving pelareorep and Tecentriq®, Cohort 1 demonstrated widespread viral replication in the majority of tumors with the creation of a pro-inflammatory effect i...
Mar 05, 2020 03:00 pm ET
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta, March 5, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter and year ended December 31, 2019. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Feb 28, 2020 06:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
SAN DIEGO and CALGARY, Alberta, Feb. 28, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Thursday, March 5, 2020 following release of its fourth quarter and year end 2019 financial results.
Jan 13, 2020 06:00 am ET
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
SAN DIEGO and CALGARY, Alberta, Jan. 13, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) (TSX: ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided a recap of a Key Opinion Leader call sponsored by ROTH Capital Partners which was held on Thursday, January 9, 2020. The KOL call focused on recent data presented at the 61st American Society of Hematology Annual Meeting and Exposition and highlighted that carfilzomib promotes reovirus infection, that pelareorep upregulates PD-L1, and that delivery of additional data from ong
Jan 09, 2020 06:00 am ET
Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients. The call, "Proteasome Inhibitors Augment Pelareorep in Multiple Myeloma" will feature Dr. Flavia Pichiorri Ph.D. and Dr. Craig Hofmeister M.D., both of whom are working on ongoing multiple myeloma studies with Oncolytics' oncolytic virus, pelareorep.
Dec 12, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 12, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the acceptance of an abstract highlighting new biomarker data from the randomized study NCI 8601: Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer. The data will be part of a poster presentation at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO, January 23 - 25, 2
Dec 09, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology
Pre-clinical and clinical data demonstrate synergies between pelareorep and the proteasome inhibitor carfilzomib through inflammation, apoptosis and tumor responses
Dec 06, 2019 07:00 am ET
Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 6, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it received written notice from Nasdaq stating that it's minimum bid price deficiency has been cured, it is in compliance with the applicable listing standard and the matter is now closed.
Dec 03, 2019 07:00 am ET
Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue
Pelareorep is the only oncolytic virus with meaningful clinical data demonstrating intravenous delivery and replication in tumor tissue
Nov 12, 2019 04:00 pm ET
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights
Highlights positive synergies in CDK 4/6 inhibitor combination, as most recent data catalyst
Nov 12, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Exercise of Warrants
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the exercise of warrants from it's August 2019 financing.
Nov 08, 2019 07:00 am ET
Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
Immuno-oncolytic virus replicates exclusively in tumor tissue and induces new T cell clonesDecrease in regulatory T cells leads to increased immune surveillance to fight cancer
Nov 07, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 7, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract highlighting the pre-clinical results of combining pelareorep with the proteasome inhibitor carfilzomib in the treatment of multiple myeloma. The abstract was published online as part of the 2019 American Society of Hematology Annual Meeting & Exhibition.
Nov 05, 2019 07:00 am ET
Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 5, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Tuesday, November 12, 2019 following release of its third quarter 2019 financial results.
Oct 31, 2019 07:00 am ET
Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye’s Clinical Progress
Adlai received National Medical Products Administration approval for phase 3 clinical trials in China
Oct 22, 2019 07:00 am ET
Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer
Study seeks to confirm predictive and prognostic biomarkers demonstrating pelareorep can expand application of checkpoint inhibitors in HR+-metastatic breast cancer
Oct 17, 2019 07:00 am ET
Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is pleased to announce the appointment of Leonard Kruimer, MBA, CPA, to Oncolytics' Board of Directors.
Oct 15, 2019 07:00 am ET
Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors
Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous delivery
Oct 01, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the acceptance of an abstract highlighting data from the AWARE-1 study to be presented at the Society for Immunotherapy of Cancer (SITC). The 34th Annual SITC Meeting will be held November 6-10, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.
Sep 30, 2019 07:00 am ET
Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its President and Chief Executive Officer, Matt Coffey, Ph.D., MBA, was presented with the Scientific Achievement and Innovation Award by BioAlberta, the province's life sciences industry association. BioAlberta recognized several industry leaders for their innovation and achievements during its Annual AGM, Awards Gala and Industry Showcase at the Westin Edmonto
Sep 25, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will have an oral presentation at the 12th Annual International Oncolytic Virus Conference. The conference takes place at the Mayo Civic Center in Rochester, Minnesota, from October 9 - 12.
Sep 23, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Upcoming Conference Participation
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will be presenting on the Company's pipeline progress, robust data catalysts and operational milestones, at the following investor conferences:
Sep 20, 2019 07:00 pm ET
Oncolytics Biotech(R) Receives Nasdaq Notification Letter
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company's common shares listed on Nasdaq was belo
Sep 17, 2019 07:00 am ET
Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will present at the Ladenburg Thalmann Healthcare Conference at 11:00 am Eastern Time on Tuesday, September 24, 2019. The conference is being held on September 24, 2019 at the Hotel Sofitel in New York City.
Sep 05, 2019 07:00 am ET
Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 5, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Kirk Look, Chief Financial Officer of Oncolytics Biotech, will present at the H.C. Wainwright 21st Annual Global Investment Conference at 5:30 pm Eastern Time on Monday, September 9, 2019. The conference is being held September 8-10, 2019 at the Lotte New York Palace Hotel.
Sep 04, 2019 07:00 am ET
Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 4, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced it will host a conference call and live webcast for Analysts and Institutional Investors at 8:30 a.m. ET on Thursday, September 5, 2019. The call will focus on a clinical and business development update, the current financial position and the recently updated list of catalysts and milestones.
Aug 16, 2019 08:55 am ET
Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 16, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the closing of its previously announced underwritten public offering (the “Offering”). Oncolytics sold 4,619,773 common shares and warrants to purchase up to 4,619,773 common shares, at a purchase price of USD $0.81 (approximately CDN $1.07) per share and warrant, for gross proceeds of approximately US
Aug 14, 2019 02:30 pm ET
CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
This is a correction to our previous announcement to highlight currency of the pricing
Aug 14, 2019 08:45 am ET
Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants
SAN DIEGO, CA & CALGARY, AB / ACCESSWIRE / August 14, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 4,619,773 common shares and warrants to purchase up to 4,619,773 common shares at a combined public offering price of $0.81 per share and warrant, resulting in gross proceeds of approximately USD 3.7M. Each warrant has an exercise
Jun 05, 2019 07:00 am ET
Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
"Our co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer reflects a growing interest in the potential synergistic effect of oncolytic viruses and immune checkpoint inhibitors and provides yet another point of validation for our technology," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. "We believe pelareorep has broad applicability to boost the effectiveness of a range of checkpoint inhibitors across multiple cancer indications. We are excited to work with Merck KGaA, Darmstadt, Germany, and Pfizer and look forward to quic
Jun 05, 2019 07:00 am ET
Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA
SAN DIEGO, CA, and CALGARY, AB / ACCESSWIRE / June 5, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that the company will host a conference call to discuss the co-development agreement with Pfizer and Merck KGaA.
May 16, 2019 07:00 am ET
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting
- Early and durable T cell clone expansion correlates with survival -- Pelareorep-induced upregulation of pro inflammatory genes was observed in patients who derived clinical benefit -- Pelareorep primes the immune system, supporting combination treatment with checkpoint inhibitors -
May 03, 2019 07:00 am ET
Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights
- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep -
May 03, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the voting results from its Annual General Meeting of Shareholders held on Thursday, May 2nd, 2019. A total of 46.21% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
Apr 23, 2019 07:00 am ET
Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would present at the 2019 Bloom Burton & Co. Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 11:00 am ET, on Tuesday, April 30, 2019, at the Metro Toronto Convention Centre, Toronto, Ontario.
Apr 08, 2019 07:00 am ET
Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 8, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient has been treated in the AWARE-1 window of opportunity (WOO) study that is being conducted in collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer. Patients will receive the appropriate intervention for their breast cancer sub-type, plus pelareorep, with or without Tecentriq® (atez
Apr 04, 2019 07:00 am ET
Apr 03, 2019 07:00 am ET
Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 3, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will present at the 18th Annual Needham Healthcare Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 1:30 pm ET, on Wednesday, April 10, 2019 at the Westin Grand Central Hotel in New York City.
Apr 02, 2019 07:00 am ET
Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019
- Clinical data highlight potential utility of T cell clonality as a predictive and prognostic biomarker of pelareorep therapy -
Mar 28, 2019 07:00 am ET
Mar 08, 2019 07:00 am ET
Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights
- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep -
Mar 01, 2019 07:00 am ET
Oncolytics Biotech(R) to Host Conference Call to Discuss Year End Financial Results and Operational Highlights
CALGARY, AB and SAN DIEGO, CA / March 1, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call and live webcast for Analysts and Institutional Investors at 8:30 a.m. ET on Friday, March 8, 2019 following release of its year end 2018 financial results.
Feb 27, 2019 04:55 pm ET
Oncolytics Biotech(R) Presents Biomarker Data in Second-line Pancreatic Cancer at AACR
Data identifies a simple blood test that predicts clinical response to pelareorep
Feb 11, 2019 07:00 am ET
Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer
Combination study with immune checkpoint inhibitor Tecentriq® to corroborate key biomarker and checkpoint inhibitor data in support of a registration pathway
Feb 04, 2019 07:00 am ET
Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 4, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would present at the 21st Annual BIO CEO & Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 2:30 pm ET, on Monday, February 11, 2019, in the Herald/Soho Room at the New York Marriott Marquis.
Dec 12, 2018 07:00 am ET
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and...
Dec 03, 2018 07:00 am ET
Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Expo
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a poster presentation made at the American Society of Hematology (ASH) Annual Meeting &...
Nov 29, 2018 07:00 am ET
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., who has been working as a consultant for Oncolytics for the...
Nov 26, 2018 08:00 am ET
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 2 study combining pelareorep with Merck’s...
Nov 13, 2018 07:00 am ET
Oncolytics Biotech® Announces Attendance of Upcoming Conferences
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the Company is scheduled to attend the following upcoming conferences: Jefferies 2018...
Nov 12, 2018 07:00 am ET
Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced financial results and operational highlights for the quarter ended September 30, 2018. All...
Nov 09, 2018 07:00 am ET
Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that data will be presented demonstrating pelareorep’s ability to upregulate PD-L1 during...
Nov 05, 2018 07:00 am ET
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call and live webcast for Analysts and Institutional Investors at...
Nov 01, 2018 07:00 am ET
Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced publication of an abstract on pelareorep to be presented at the American Society of Hematology...
Oct 24, 2018 08:25 pm ET
Oncolytics Biotech® Establishes New At-The-Market Facility
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus that turns cold tumors hot, today announced that it entered into an At-the-Market (ATM) equity offering sales...
Oct 22, 2018 07:00 am ET
Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced positive clinical trial results for pelareorep in the treatment of...
Oct 11, 2018 07:00 am ET
Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced publication of an abstract on pelareorep (formerly known as REOLYSIN)...
Oct 02, 2018 07:00 am ET
Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced publication of important research in the peer-reviewed journal Cancer...
Sep 28, 2018 08:36 am ET
Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC
Oncolytics Biotech® Inc. (NASDAQ: ONCY), (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the execution of a Common Stock Purchase Agreement (“Agreement”) for up...
Sep 26, 2018 07:00 am ET
Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference
Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it will present at the Ladenburg Thalmann 2018 Healthcare...
Sep 19, 2018 04:00 pm ET
Oncolytics Biotech® Provides Corporate and Clinical Update
Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a corporate update would be provided in a conference call and webcast...
Sep 17, 2018 07:00 am ET
Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care
Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a second study in multiple myeloma.  This study will combine...
Sep 10, 2018 07:00 am ET
Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a clinical collaboration with SOLTI, an academic research...
Sep 06, 2018 07:00 am ET
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has entered into a Master Clinical Supply Agreement...
Aug 03, 2018 07:00 am ET
Oncolytics Biotech® Reports 2018 Second Quarter Results
Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial results and operational highlights for the quarter...
Jul 31, 2018 07:00 am ET
Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference
Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it will present at the Canaccord Genuity 38th Annual...
Jun 05, 2018 12:49 pm ET
Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares
Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the closing of its previously announced underwritten public...
Jun 04, 2018 09:00 am ET
Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting
Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a key poster presentation at the American Society of Clinical...
Jun 01, 2018 09:13 am ET
Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares
Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the pricing of its underwritten public offering of 1,372,213...
Jun 01, 2018 07:40 am ET
Oncolytics Biotech® Announces Listing on Nasdaq Capital Market
Oncolytics Biotech® Inc. (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that its shares of common stock were approved for listing on...
May 31, 2018 04:27 pm ET
Oncolytics Biotech® Announces Public Offering of Common Shares
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYD), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has commenced a registered underwritten public...
May 29, 2018 12:05 pm ET
Oncolytics Biotech® Announces New OTCQX Ticker Symbol
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYD), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that following its share consolidation, the Company’s new...
May 25, 2018 07:00 am ET
Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a collaboration with the Keck School of Medicine of University...
May 22, 2018 05:13 pm ET
Oncolytics Biotech® Has Applied to List its Common Shares on Nasdaq and Announces Share Consolidation
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has applied to list its common shares on the Nasdaq...
May 17, 2018 07:00 am ET
Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced an investigator sponsored study (IST) supported by Merck Inc....
May 16, 2018 05:00 pm ET
Oncolytics Biotech® Announces Publication of REOLYSIN® Abstract for the ASCO 2018 Annual Meeting
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced publication of an abstract on pelareorep for the American...
May 11, 2018 07:00 am ET
Oncolytics Biotech® Reports 2018 First Quarter Results
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial results and operational highlights for the quarter...
May 10, 2018 07:00 am ET
Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has reached an agreement with the U.S. Food and Drug...
May 04, 2018 04:00 pm ET
Oncolytics Biotech® Announces Voting Results from its Annual General Meeting of Shareholders
Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the voting results from its Annual Meeting of Shareholders...
Apr 26, 2018 07:00 am ET
Oncolytics Biotech(R) Announces Details of 2018 Annual General Meeting of Shareholders
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that its 2018 Annual General Meeting of Shareholders will be...
Apr 18, 2018 07:00 am ET
Oncolytics Biotech(R) Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018
Preclinical models proved pelareorep increased PD-L1 expression in microsatellite stable (MSS) colorectal cancer cells (CRC) -- Demonstrated efficacy of pelareorep and anti-PD1 agent combination -Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF),...
Apr 17, 2018 04:00 pm ET
Oncolytics Biotech(R) Announces Management Change
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that Andres Gutierrez, Chief Medical Officer at...
Apr 10, 2018 07:00 am ET
Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that a poster highlighting the effectiveness of...
Apr 04, 2018 10:42 am ET
Oncolytics Biotech(R) to Present at the MicroCap Conference
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that it will be presenting at the MicroCap...
Mar 20, 2018 07:00 am ET
Oncolytics Biotech(R) Scientist Selected to Participate in the Society of Immunotherapy of Cancer's (SITC) METIOR Incubator Program
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that Grey Wilkinson, Ph.D., scientist of...
Mar 14, 2018 05:00 pm ET
Oncolytics Biotech(R) Announces Publication of REOLYSIN(R) Abstract for the AACR 2018 Annual Meeting
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced publication of an abstract on pelareorep for the...
Mar 09, 2018 07:00 am ET
Oncolytics Biotech(R) Inc. Announces 2017 Year-End Results
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced its financial results and operational highlights for...
Mar 08, 2018 07:00 am ET
Oncolytics Biotech(R) Chief Medical Officer to Facilitate Roundtable Discussion at the US Immuno-Oncology Strategy Meeting
Oncolytics Biotech®, Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Feb 27, 2018 07:00 am ET
Oncolytics Biotech(R) to Present REOLYSIN(R) at the 2018 Precision: Breast Cancer World R&D Summit
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Feb 23, 2018 05:27 pm ET
Oncolytics Biotech(R) Announces Results from Special Meeting of Shareholders
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Feb 14, 2018 07:00 am ET
Oncolytics Biotech(R) to Present at the RBC Capital Markets 2018 Healthcare Conference
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Feb 01, 2018 07:00 am ET
Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN(R)
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Jan 29, 2018 07:00 am ET
Oncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Jan 25, 2018 07:00 am ET
Oncolytics Biotech(R) Named to the 2018 OTCQX Best 50
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Jan 19, 2018 04:00 pm ET
Oncolytics Biotech(R) Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Jan 16, 2018 05:00 pm ET
Oncolytics Biotech(R) Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors...
Dec 27, 2017 06:00 am ET
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
CALGARY and SAN DIEGO, CA, Dec. 27, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced that data from REO 024 will be presented at the 2018 Gastrointestinal Cancers Symposium sponsored by ASCO, January 18 – 20, 2018, in San Francisco. The poster presentation by Dr. Devalingam Mahalingam, M.D. Ph.D., Associate Professor of Medicine (Hematol
Dec 27, 2017 06:00 am ET
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
CALGARY and SAN DIEGO, CA, Dec. 27, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced that data from REO 024 will be presented at the 2018 Gastrointestinal Cancers Symposium sponsored by ASCO, January 18 – 20, 2018, in San Francisco. The poster presentation by Dr. Devalingam Mahalingam, M.D. Ph.D., Associate Professor of Medicine (...
Nov 30, 2017 06:00 am ET
Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer
CALGARY and SAN DIEGO, Nov. 30, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced the establishment of its Scientific Advisory Board (SAB).  The SAB will provide Oncolytics with significant clinical expertise and experience in breast cancer drug development in both the U.S. and Europe with the following initial members:
Nov 30, 2017 06:00 am ET
Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer
CALGARY and SAN DIEGO, Nov. 30, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced the establishment of its Scientific Advisory Board (SAB).  The SAB will provide Oncolytics with significant clinical expertise and experience in breast cancer drug development in both the U.S. and Europe with the following initial members: ...
Nov 16, 2017 05:00 pm ET
Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®
Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 million, and eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercialization milestones Upon Adlai Nortye's commercialization of REOLYSIN®, Oncolytics is eligible to receive double digit royalty payments Management to host webcast and conference call tomorrow, November 17, 2017 at 8:30 am ET for Analysts and Institutional Investors C...
Nov 16, 2017 05:00 pm ET
Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®
Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 million, and eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercialization milestones Upon Adlai Nortye's commercialization of REOLYSIN®, Oncolytics is eligible to receive double digit royalty payments Management to host webcast and conference call tomorrow, November 17, 2017 at 8:30 am ET for Analysts and Institutional Investors C
Nov 08, 2017 07:00 am ET
Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results
CALGARY, and SAN DIEGO, CA, Nov. 8, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced its financial results and operational highlights for the quarter ended September 30, 2017.
Nov 08, 2017 07:00 am ET
Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results
CALGARY, and SAN DIEGO, CA, Nov. 8, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced its financial results and operational highlights for the quarter ended September 30, 2017....
Nov 02, 2017 08:00 am ET
Oncolytics Biotech® Appoints Deborah Brown to Board of Directors
CALGARY and SAN DIEGO, CA, Nov. 2, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced the appointment of Deborah M. Brown, B.Sc., M.B.A., to Oncolytics' Board of Directors.
Nov 02, 2017 08:00 am ET
Oncolytics Biotech® Appoints Deborah Brown to Board of Directors
CALGARY and SAN DIEGO, CA, Nov. 2, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced the appointment of Deborah M. Brown, B.Sc., M.B.A., to Oncolytics' Board of Directors....
Oct 11, 2017 08:00 am ET
Oncolytics Biotech® to Present at the 2017 BIO Investor Forum
Presenting clinical data of REOLYSIN® in metastatic breast cancer and the Company's strategic objectives...
Oct 11, 2017 08:00 am ET
Oncolytics Biotech® to Present at the 2017 BIO Investor Forum
Presenting clinical data of REOLYSIN® in metastatic breast cancer and the Company's strategic objectives
Sep 19, 2017 08:00 am ET
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference
Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, to present on the clinical progress and robust safety findings of using reovirus as an immuno-oncology viral agent to treat cancer
Sep 19, 2017 08:00 am ET
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference
Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, to present on the clinical progress and robust safety findings of using reovirus as an immuno-oncology viral agent to treat cancer...
Sep 18, 2017 08:00 am ET
Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer
Outcome supports focus on HR+/HER2- patient group that reported an effective doubling of median overall survival from 10.8 to 21.0 months
Sep 18, 2017 08:00 am ET
Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer
Outcome supports focus on HR+/HER2- patient group that reported an effective doubling of median overall survival from 10.8 to 21.0 months...
Sep 14, 2017 08:00 am ET
Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study
CALGARY and SAN DIEGO, Sept. 14, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN® (pelareorep), a first-in-class, systemically delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that the first patient has been treated in the Phase 1b trial MUK eleven, studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Revlimid® or Imnovid® as a rescue treatment in relapsing myeloma patients.
Sep 14, 2017 08:00 am ET
Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study
CALGARY and SAN DIEGO, Sept. 14, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN® (pelareorep), a first-in-class, systemically delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that the first patient has been treated in the Phase 1b trial MUK eleven, studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Revlimid® or Imnovid® as a rescue treatment in relapsing myeloma patients....
Sep 11, 2017 08:00 am ET
Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress
Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients...
Sep 11, 2017 08:00 am ET
Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress
Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients
Aug 03, 2017 08:00 am ET
Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results
CALGARY and SAN DIEGO, CA, Aug. 3, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced its financial results and operational highlights for the quarter ended June 30, 2017.
Aug 03, 2017 08:00 am ET
Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results
CALGARY and SAN DIEGO, CA, Aug. 3, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced its financial results and operational highlights for the quarter ended June 30, 2017....
Aug 01, 2017 08:00 am ET
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
CALGARY, AB and SAN DIEGO, CA, Aug. 1, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) will present at the Canaccord Genuity 37th Annual Growth Conference.  The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 9:00 am ET, on Thursday, August 10, 2017 in the Hong Kong Room at the Intercontinental Hotel. The conference takes place on August 9th & 10th in Boston, MA.
Aug 01, 2017 08:00 am ET
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
CALGARY, AB and SAN DIEGO, CA, Aug. 1, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) will present at the Canaccord Genuity 37th Annual Growth Conference.  The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 9:00 am ET, on Thursday, August 10, 2017 in the Hong Kong Room at the Intercontinental Hotel. The conference takes place on August 9th & 10th in Boston, MA....
Jul 26, 2017 08:00 am ET
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
Announces end-of-phase 2 meeting with the U.S. Food and Drug Administration...
Jul 26, 2017 08:00 am ET
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
Announces end-of-phase 2 meeting with the U.S. Food and Drug Administration
Jun 29, 2017 08:00 am ET
Jun 29, 2017 08:00 am ET
Jun 27, 2017 08:00 am ET
Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego
CALGARY and SAN DIEGO, June 27, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced that it has opened an office in San Diego, California.  The office will support investor relations, business development and clinical operations functions.
Jun 27, 2017 08:00 am ET
Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego
CALGARY and SAN DIEGO, June 27, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced that it has opened an office in San Diego, California.  The office will support investor relations, business development and clinical operations functions....
Jun 01, 2017 10:26 am ET
Oncolytics Biotech® Announces Closing of Public Offering of Units
CALGARY, June 1, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the closing of its previously announced underwritten public offering. Oncolytics sold 16,445,000 units (Units) (including Units issued pursuant to the exercise in full of the over-allotment option granted by the Company to the underwriters) at a purchase price of $0.70 per Unit for gross proceeds of approximately $11.5 million (the Offering). The net proceeds of the Offering were approximately $10.6 million, after deducting the underwriting commissions and other e...
Jun 01, 2017 10:26 am ET
Oncolytics Biotech® Announces Closing of Public Offering of Units
/THIS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
May 24, 2017 11:45 am ET
IIROC Trade Resumption - ONC
TORONTO, May 24, 2017 /CNW/ - Trading resumes in:
May 24, 2017 11:32 am ET
Oncolytics Biotech® Prices Public Offering of Units
/THIS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
May 24, 2017 11:32 am ET
Oncolytics Biotech® Prices Public Offering of Units
CALGARY, May 24, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the pricing of an underwritten public offering of 14,300,000 units (Units) at a purchase price of $0.70 per Unit for gross proceeds of $10,010,000 (the Offering). Each Unit will be comprised of one common share (Common Share) of the Company and one common share purchase warrant (Warrant). Each Warrant will entitle the holder thereof to purchase one common share (Warrant Share) in the capital of the Company, for a period of 5 years following the Closing Date of the Of
May 24, 2017 11:32 am ET
Oncolytics Biotech® Prices Public Offering of Units
CALGARY, May 24, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the pricing of an underwritten public offering of 14,300,000 units (Units) at a purchase price of $0.70 per Unit for gross proceeds of $10,010,000 (the Offering). Each Unit will be comprised of one common share (Common Share) of the Company and one common share purchase warrant (Warrant). Each Warrant will entitle the holder thereof to purchase one common share (Warrant Share) in the capital of the Company, for a period of 5 years following the Closing Date of...
May 24, 2017 11:01 am ET
IIROC Trading Halt - ONC
TORONTO, May 24, 2017 /CNW/ - The following issues have been halted by IIROC:
May 23, 2017 08:08 pm ET
Oncolytics Biotech® Announces Proposed Public Offering
CALGARY, May 23, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced that it will undertake a public offering (the "Offering") of securities of the Company ("Securities").   The Offering will be effected pursuant to a prospectus supplement (the "Prospectus Supplement") to the Company's base shelf prospectus dated February 16, 2016 (together with the Prospectus Supplement, the "Prospectus"), to be filed with securities regulators in each of the Provinces of Canada, other than Quebec. The Securities may also be offered for sale in th...
May 23, 2017 05:09 pm ET
Oncolytics Biotech® Announces Proposed Public Offering
CALGARY, May 23, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced that it will undertake a public offering (the "Offering") of securities of the Company ("Securities"). The Offering will be effected pursuant to a prospectus supplement (the "Prospectus Supplement") to the Company's base shelf prospectus dated February 16, 2016 (together with the Prospectus Supplement, the "Prospectus"), to be filed with securities regulators in each of the Provinces of Canada, other than Quebec. The Securities may also be offered for sale in the United
May 23, 2017 08:00 am ET
Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017
CALGARY, May 23, 2017 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (OTCQX:ONCYF) (Oncolytics or the Company) today announced that Dr. Andres A. Gutierrez, Chief Medical Officer of Oncolytics Biotech Inc. will present at the World Immunotherapy Congress USA 2017 in a session on Tuesday, May 23rd, 2017 at 3:20 pm PT. Dr. Gutierrez's presentation will focus on the use of "REOLYSIN® as potential novel immuno-oncology viral agent for the anti-cancer armamentarium". The conference takes place on May 23rd and 24th at the Hilton San Diego Resort and Spa in San Diego, CA....
May 23, 2017 08:00 am ET
Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017
CALGARY, May 23, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC) (OTCQX:ONCYF) (Oncolytics or the Company) today announced that Dr. Andres A. Gutierrez, Chief Medical Officer of Oncolytics Biotech Inc. will present at the World Immunotherapy Congress USA 2017 in a session on Tuesday, May 23rd, 2017 at 3:20 pm PT. Dr. Gutierrez's presentation will focus on the use of "REOLYSIN® as potential novel immuno-oncology viral agent for the anti-cancer armamentarium". The conference takes place on May 23rd and 24th at the Hilton San Diego Resort and Spa in San Diego, CA.
May 17, 2017 06:16 pm ET
Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers
CALGARY, May 17, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the publication of abstracts for an open-label phase 1b trial in patients with metastatic adenocarcinoma of the pancreas (MAP) (REO 024) and an open-label, randomized, phase 2 study in metastatic castration resistant prostate cancer (mCRPC). Data from the studies will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, in Chicago, IL.
May 17, 2017 06:16 pm ET
Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers
CALGARY, May 17, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced the publication of abstracts for an open-label phase 1b trial in patients with metastatic adenocarcinoma of the pancreas (MAP) (REO 024) and an open-label, randomized, phase 2 study in metastatic castration resistant prostate cancer (mCRPC). Data from the studies will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, in Chicago, IL....
May 08, 2017 08:00 am ET
Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer
CALGARY, May 8, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for REOLYSIN®, the Company's proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer.
May 08, 2017 08:00 am ET
Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer
CALGARY, May 8, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for REOLYSIN®, the Company's proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer....